Cargando…
Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model
A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources. This study assesses three approaches to DNL suppression in a newly developed dietary NASH mouse...
Autores principales: | Gapp, Berangere, Jourdain, Marie, Bringer, Pauline, Kueng, Benjamin, Weber, Delphine, Osmont, Arnaud, Zurbruegg, Stefan, Knehr, Judith, Falchetto, Rocco, Roma, Guglielmo, Dietrich, William, Valdez, Reginald, Beckmann, Nicolau, Nigsch, Florian, Sanyal, Arun J., Ksiazek, Iwona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939503/ https://www.ncbi.nlm.nih.gov/pubmed/31909359 http://dx.doi.org/10.1002/hep4.1443 |
Ejemplares similares
-
Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019) -
Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment
por: Kim, Munkyung, et al.
Publicado: (2015) -
Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
por: Wang, Zhong-Yi, et al.
Publicado: (2021) -
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
por: Boeckmans, Joost, et al.
Publicado: (2019) -
REV-ERB agonism improves liver pathology in a mouse model of NASH
por: Griffett, Kristine, et al.
Publicado: (2020)